Despite initial benefits, fewer than 10% of EGFR-mutated NSCLC patients on osimertinib monotherapy survive five years. A significant portion (25-40%) never even receive a second-line treatment, highlighting the limitations of this once-standard approach.
Data from the FLORA-2 trial (osimertinib + chemo) shows a strong correlation between the duration of pemetrexed exposure and overall survival. Patients receiving it for over 18 months had significantly better outcomes, emphasizing the importance of maintaining the chemotherapy component.
Unlike many cancer therapies, the survival advantage of the amivantamab + lazertinib combination in the MARIPOSA trial isn't static. The benefit progressively increases at 24, 36, and 42 months, suggesting a durable, long-term impact on disease control that grows with extended follow-up.
When a lung cancer patient is too symptomatic to wait for genomic testing results, the expert consensus is to initiate treatment with chemotherapy alone. Adding immunotherapy upfront is ill-advised, as its use in EGFR-mutated patients (a common finding) can be detrimental.
The standard of care for newly diagnosed EGFR-mutated non-small cell lung cancer has shifted from osimertinib monotherapy to combination regimens. Experts agree that combinations (e.g., osimertinib/chemo) should be the default choice, with monotherapy now reserved for cases with significant tolerability concerns.
The intravenous amivantamab regimen has faced adoption challenges due to practical burdens on patients and clinics, including long infusion times, infusion reactions, and scheduling difficulties. The shift to a subcutaneous formulation is a critical step to overcome these non-clinical barriers.
For patients with atypical (non-exon 19/21) EGFR mutations, the treatment landscape has expanded. Recent ASCO guideline updates now recommend three different first-line options—afatinib, osimertinib, and amivantamab with lazertinib—signaling a move away from a one-size-fits-all approach for this diverse patient subgroup.
The toxicity profile of amivantamab has been transformed by modern management. Data from studies like COCOON (prophylaxis) and PALOMA-3 (subcutaneous formulation) show dramatically lower rates of adverse events and discontinuations compared to the original MARIPOSA trial, rendering early toxicity tables less relevant.
To improve long-term tolerability of amivantamab, some experts advocate for a "marathon, not a sprint" approach. This involves aggressive dose holds or reductions at the earliest signs of toxicity, even low-grade, to prevent side effects from escalating and ensure patients can remain on effective therapy longer.
In the PALOMA-3 trial, the subcutaneous formulation of amivantamab not only reduced infusion-related reactions but also unexpectedly showed a potential efficacy benefit over the IV version, including a statistically significant difference in overall survival. This suggests the route of administration may have biological implications.
Due to the high likelihood of long-term survival with modern targeted therapies, whole brain radiation (WBRT) is considered contraindicated for patients with EGFR-mutated lung cancer, irrespective of brain metastases count. The risk of severe neurocognitive decline outweighs any benefit, making systemic therapy and SRS preferred.
For EGFR-mutated lung cancer patients experiencing cardiac toxicity like QTc prolongation with osimertinib, lazertinib presents a viable alternative. Its lower rate of cardiac side effects allows for continued third-generation TKI therapy in a specific patient subset where osimertinib may be contraindicated.
When treating EGFR-mutated NSCLC that has progressed on osimertinib, leading oncologists advocate for continuing the TKI even when adding a new agent like datopotamab deruxtecan. This off-label practice is based on strong biological rationale and consistent trial data showing benefit from maintaining EGFR inhibition.